Procuritas Capital Investors has acquired a majority stake in Nordic Biomarker, aiming to enhance its position in the global coagulation testing market while promoting sustainability in healthcare.

Information on the Target

Procuritas Capital Investors has announced its acquisition of a majority stake in Nordic Biomarker, a Swedish company established in 2007. Nordic Biomarker specializes in providing high-quality reagents for in vitro diagnostic (IVD) coagulation analyzers. The company has rapidly expanded its product portfolio, which includes both routine and specialty reagents for coagulation testing, serving clients globally under various brand names, as well as through its Medirox-branded kits. Production occurs at modern facilities in Umeå and Linköping, Sweden, and the company employs approximately 80 individuals.

In 2017, Nordic Biomarker formed a partnership with Medirox, enhancing their offerings with CE-marked reagent kits. The company has been investing heavily in research and development, showing commitment to innovation with several new products currently in the pipeline. In 2021, Nordic Biomarker reported revenues of 131 million SEK, demonstrating its robust growth trajectory in the competitive medical diagnostics field.

Industry Overview in Sweden

Sweden's healthcare industry is recognized for its innovation and is continually evolving, boosted by advances in medical technology and an increasing emphasis on personalized healthcar